Neural stem cells  Disease modeling
52282455
Neural stem cells for disease modeling and evaluation of therapeutics for Tay Sachs disease
BackgroundTay Sachs disease (TSD) is a rare neurodegenerative disorder caused by autosomal recessive mutations in the HEXA gene on chromosome 15 that encodes b hexosaminidase. Deficiency in HEXA results in accumulation of GM2 ganglioside, a glycosphingolipid, in lysosomes. Currently, there is no effective treatment for TSD.ResultsWe generated induced pluripotent stem cells (iPSCs) from two TSD patient dermal fibroblast lines and further differentiated them into neural stem cells (NSCs) The TSD neural stem cells exhibited a disease phenotype of lysosomal lipid accumulation. The Tay Sachs disease NSCs were then used to evaluate the therapeutic effects of enzyme replacement therapy (ERT) with recombinant human Hex A protein and two small molecular compounds: hydroxypropyl b cyclodextrin (HPbCD) and d tocopherol. Using this disease model, we observed reduction of lipid accumulation by employing enzyme replacement therapy as well as by the use of HPbCD and d tocopherol.ConclusionOur results demonstrate that the Tay Sachs disease NSCs possess the characteristic phenotype to serve as a cell based disease model for study of the disease pathogenesis and evaluation of drug efficacy. The enzyme replacement therapy with recombinant Hex A protein and two small molecules (cyclodextrin and tocopherol) significantly ameliorated lipid accumulation in the Tay Sachs disease cell model.
Orphanet Journal of Rare Diseases
Mylinh Vu Rong Li Amanda Baskfield Billy Lu Atena Farkhondeh Kirill Gorshkov Omid Motabar Jeanette K Beers Guokai Chen Jizhong Zou Angela Johana Espejo-Mojica Alexander Rodriguez-Lopez Carlos Javier Almeciga-Diaz Luis A Barrera Xuntian Jiang Daniel S Ory Juan Jose Marugan Wei Zheng
1030788
Neural stem cells for disease modeling of Wolman disease and evaluation of therapeutics
BackgroundWolman disease (WD) is a rare lysosomal storage disorder that is caused by mutations in the LIPA gene encoding lysosomal acid lipase (LAL) Deficiency in LAL function causes accumulation of cholesteryl esters and triglycerides in lysosomes. Fatality usually occurs within the first year of life. While an enzyme replacement therapy has recently become available, there is currently no small molecule drug treatment for WD.ResultsWe have generated induced pluripotent stem cells (iPSCs) from two WD patient dermal fibroblast lines and subsequently differentiated them into neural stem cells (NSCs) The WD NSCs exhibited the hallmark disease phenotypes of neutral lipid accumulation, severely deficient LAL activity, and increased LysoTracker dye staining. Enzyme replacement treatment dramatically reduced the WD phenotype in these cells. In addition, d tocopherol (DT) and hydroxypropyl beta cyclodextrin (HPBCD) significantly reduced lysosomal size in WD NSCs, and an enhanced effect was observed in DT/HPBCD combination therapy.ConclusionThe results demonstrate that these WD NSCs are valid cell based disease models with characteristic disease phenotypes that can be used to evaluate drug efficacy and screen compounds. DT and HPBCD both reduce LysoTracker dye staining in WD cells. The cells may be used to further dissect the pathology of WD, evaluate compound efficacy, and serve as a platform for high throughput drug screening to identify new compounds for therapeutic development.
Orphanet Journal of Rare Diseases
Francis Aguisanda Charles D Yeh Catherine Z Chen Rong Li Jeanette K Beers Jizhong Zou Natasha Thorne Wei Zheng
18668249
Neural Differentiation of Human Pluripotent Stem Cells for Nontherapeutic Applications: Toxicology, Pharmacology, and In Vitro Disease Modeling
Human pluripotent stem cells (hPSCs) derived from either blastocyst stage embryos (hESCs) or reprogrammed somatic cells (iPSCs) can provide an abundant source of human neuronal lineages that were previously sourced from human cadavers, abortuses, and discarded surgical waste. In addition to the well known potential therapeutic application of these cells in regenerative medicine, these are also various promising nontherapeutic applications in toxicological and pharmacological screening of neuroactive compounds, as well as for in vitro modeling of neurodegenerative and neurodevelopmental disorders. Compared to alternative research models based on laboratory animals and immortalized cancer derived human neural cell lines, neuronal cells differentiated from hPSCs possess the advantages of species specificity together with genetic and physiological normality, which could more closely recapitulate in vivo conditions within the human central nervous system. This review critically examines the various potential nontherapeutic applications of hPSC derived neuronal lineages and gives a brief overview of differentiation protocols utilized to generate these cells from hESCs and iPSCs.
Stem cells international
May Shin Yap K R Ganesan Nathan Yin Yeo Lee Wei Lim Chit Laa Poh M Richards Wei Ling Lim Iekhsan Othman Boon Chin Heng
49683737
3D Culture Method for Alzheimer's Disease Modeling Reveals Interleukin 4 Rescues Ab42 Induced Loss of Human Neural Stem Cell Plasticity.
Neural stem cells (NSCs) constitute an endogenous reservoir for neurons that could potentially be harnessed for regenerative therapies in disease contexts such as neurodegeneration. However, in Alzheimer's disease (AD) NSCs lose plasticity and thus possible regenerative capacity. We investigate how NSCs lose their plasticity in AD by using starPEG heparin based hydrogels to establish a reductionist 3D cell instructive neuro microenvironment that promotes the proliferative and neurogenic ability of primary and induced human NSCs. We find that administration of AD associated Amyloid b42 causes classical neuropathology and hampers NSC plasticity by inducing kynurenic acid (KYNA) production. Interleukin 4 restores NSC proliferative and neurogenic ability by suppressing the KYNA producing enzyme Kynurenine aminotransferase (KAT2) which is upregulated in APP/PS1dE9 mouse model of AD and in postmortem human AD brains. Thus, our culture system enables a reductionist investigation of regulation of human NSC plasticity for the identification of potential therapeutic targets for intervention in AD.
Developmental cell
Christos Papadimitriou Hilal Celikkaya Mehmet Ilyas Cosacak Violeta Mashkaryan Laura J Bray Prabesh Bhattarai Kerstin Brandt Heike Hollak Xin Chen Shuijin He Christopher L Antos Weilin Lin Alvin Kuriakose Thomas Andreas Dahl Thomas Kurth Jens Dipl Ing Friedrichs Yixin Zhang Uwe Freudenberg Carsten Werner Caghan Kizil
206129571
Process based expansion and neural differentiation of human pluripotent stem cells for transplantation and disease modeling
Robust strategies for developing patient specific, human, induced pluripotent stem cell (iPSC) based therapies of the brain require an ability to derive large numbers of highly defined neural cells. Recent progress in iPSC culture techniques includes partial to complete elimination of feeder layers, use of defined media, and single cell passaging. However, these techniques still require embryoid body formation or coculture for differentiation into neural stem cells (NSCs) In addition, none of the published methodologies has employed all of the advances in a single culture system. Here we describe a reliable method for long term, single cell passaging of PSCs using a feeder free, defined culture system that produces confluent, adherent PSCs that can be differentiated into NSCs. To provide a basis for robust quality control, we have devised a system of cellular nomenclature that describes an accurate genotype and phenotype of the cells at specific stages in the process. We demonstrate that this protocol allows for the efficient, large scale, cGMP compliant production of transplantable NSCs from all lines tested. We also show that NSCs generated from iPSCs produced with the process described are capable of forming both glia defined by their expression of S100b and neurons that fire repetitive action potentials. (c) 2013 Wiley Periodicals, Inc.
Journal of neuroscience research
Alexander E Stover David Joseph Brick Hubert E Nethercott Maria G Banuelos Lei Sun Diane K O'Dowd Philip Hitchins Schwartz
7194676
Use of human stem cells in Huntington disease modeling and translational research
Huntington disease (HD) is a devastating neurological disorder caused by an extended CAG repeat in exon 1 of the gene that encodes the huntingtin (HTT) protein. HD pathology involves a loss of striatal medium spiny neurons (MSNs) and progressive neurodegeneration affects the striatum and other brain regions. Because HTT is involved in multiple cellular processes, the molecular mechanisms of HD pathogenesis should be investigated on multiple levels. On the cellular level, in vitro stem cell models, such as induced pluripotent stem cells (iPSCs) derived from HD patients and HD embryonic stem cells (ESCs) have yielded progress. Approaches to differentiate functional MSNs from ESCs, iPSCs, and neural stem/progenitor cells (NSCs/NPCs) have been established, enabling MSN differentiation to be studied and disease phenotypes to be recapitulated. Isolation of target stem cells and precursor cells may also provide a resource for grafting. In animal models, transplantation of striatal precursors differentiated in vitro to the striatum has been reported to improve disease phenotype. Initial clinical trials examining intrastriatal transplantation of fetal neural tissue suggest a more favorable clinical course in a subset of HD patients, though shortcomings persist. Here, we review recent advances in the development of cellular HD models and approaches aimed at cell regeneration with human stem cells. We also describe how genome editing tools could be used to correct the HTT mutation in patient specific stem cells. Finally, we discuss the potential and the remaining challenges of stem cell based approaches in HD research and therapy development.
Experimental Neurology
Monika M Golas Bjoern Sander
1126420
Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann Pick Disease Type A
Niemann Pick disease type A (NPA) is a lysosomal storage disease caused by mutations in the SMPD1 gene that encodes acid sphingomyelinase (ASM) Deficiency in ASM function results in lysosomal accumulation of sphingomyelin and neurodegeneration. Currently, there is no effective treatment for NPA. To accelerate drug discovery for treatment of NPA, we generated induced pluripotent stem cells from two patient dermal fibroblast lines and differentiated them into neural stem cells. The NPA neural stem cells exhibit a disease phenotype of lysosomal sphingomyelin accumulation and enlarged lysosomes. By using this disease model, we also evaluated three compounds that reportedly reduced lysosomal lipid accumulation in Niemann Pick disease type C as well as enzyme replacement therapy with ASM. We found that a tocopherol, d tocopherol, hydroxypropyl b cyclodextrin, and ASM reduced sphingomyelin accumulation and enlarged lysosomes in NPA neural stem cells. Therefore, the NPA neural stem cells possess the characteristic NPA disease phenotype that can be ameliorated by tocopherols, cyclodextrin, and ASM. Our results demonstrate the efficacies of cyclodextrin and tocopherols in the NPA cell based model. Our data also indicate that the NPA neural stem cells can be used as a new cell based disease model for further study of disease pathophysiology and for high throughput screening to identify new lead compounds for drug development.
Stem cells translational medicine
Yan Long Miao Xu Rong Li Sheng Dai Jeanette K Beers Guokai Chen Ferri Soheilian Ulrich Baxa Mengqiao Wang Juan Jose Marugan Silvia Muro Zhiyuan Li Roscoe O Brady Wei Zheng
37800019
Human induced pluripotent stem cells in Parkinson's disease: A novel cell source of cell therapy and disease modeling
Human induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs) are two novel cell sources for studying neurodegenerative diseases. Dopaminergic neurons derived from hiPSCs/hESCs have been implicated to be very useful in Parkinson's disease (PD) research, including cell replacement therapy, disease modeling and drug screening. Recently, great efforts have been made to improve the application of hiPSCs/hESCs in PD research. Considerable advances have been made in recent years, including advanced reprogramming strategies without the use of viruses or using fewer transcriptional factors, optimized methods for generating highly homogeneous neural progenitors with a larger proportion of mature dopaminergic neurons and better survival and integration after transplantation. Here we outline the progress that has been made in these aspects in recent years, particularly during the last year, and also discuss existing issues that need to be addressed.
Progress in Neurobiology
Wen Li Shengdi Chen Jia-Yi Li
10905134
Understanding Melanocyte Stem Cells for Disease Modeling and Regenerative Medicine Applications
Melanocytes in the skin play an indispensable role in the pigmentation of skin and its appendages. It is well known that the embryonic origin of melanocytes is neural crest cells. In adult skin, functional melanocytes are continuously repopulated by the differentiation of melanocyte stem cells (McSCs) residing in the epidermis of the skin. Many preceding studies have led to significant discoveries regarding the cellular and molecular characteristics of this unique stem cell population. The alteration of McSCs has been also implicated in several skin abnormalities and disease conditions. To date, our knowledge of McSCs largely comes from studying the stem cell niche of mouse hair follicles. Suggested by several anatomical differences between mouse and human skin, there could be distinct features associated with mouse and human McSCs as well as their niches in the skin. Recent advances in human pluripotent stem cell (hPSC) research have provided us with useful tools to potentially acquire a substantial amount of human McSCs and functional melanocytes for research and regenerative medicine applications. This review highlights recent studies and progress involved in understanding the development of cutaneous melanocytes and the regulation of McSCs.
International journal of molecular sciences
Amber N Mull Ashwini Zolekar Yu-Chieh Wang
15474509
A Quantitative Framework to Evaluate Modeling of Cortical Development by Neural Stem Cells
Neural stem cells have been adopted to model a wide range of neuropsychiatric conditions in vitro. However, how well such models correspond to in vivo brain has not been evaluated in an unbiased, comprehensive manner. We used transcriptomic analyses to compare in vitro systems to developing human fetal brain and observed strong conservation of in vivo gene expression and network architecture in differentiating primary human neural progenitor cells (phNPCs) Conserved modules are enriched in genes associated with ASD, supporting the utility of phNPCs for studying neuropsychiatric disease. We also developed and validated a machine learning approach called CoNTExT that identifies the developmental maturity and regional identity of in vitro models. We observed strong differences between in vitro models, including hiPSC derived neural progenitors from multiple laboratories. This work provides a systems biology framework for evaluating in vitro systems and supports their value in studying the molecular mechanisms of human neurodevelopmental disease.
Neuron
Jason L Stein Luis de la torre-Ubieta Yuan Tian Neelroop N Parikshak Israel Hernandez Maria C Marchetto Dylan K Baker Daning Lu Cassidy R Hinman Jennifer K Lowe Eric M Wexler Alysson Renato Muotri Fred H Gage Kenneth S Kosik Daniel H Geschwind